ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2025
May Measurement Month 2022: an analysis of blood pressure screening results from Venezuela.
Article in European heart journal supplements : journal of the European Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases continue to be the main cause of death in Venezuela, and hypertension is the primary risk factor. The May Measurement Month (MMM) campaign has been conducted annually in Venezuela since 2017. In 2022 (MMM22), the campaign included 46 239 participants with a mean age of 57.3 (SD 14.9) years and 57.2% were female. The percentage of participants with hypertension was 59.0% (females: 56.1%; males: 62.9%); of those, 80.6% were aware of their condition and 78.9% were on antihypertensive medication. Among those receiving drug treatment, 58.8% were controlled to <140/90 mmHg, and of the overall hypertensive population, 46.4% were controlled. Of those taking antihypertensive medication, 58.5% received one antihypertensive drug, 31.7% two drugs, and 9.8% were on three or more drugs. When results were age-sex standardized, the prevalence of hypertension was lower at 39.9%. Other cardiovascular (CV) risk factors were also identified: 8.3% reported having diabetes, 21.0% were obese (body mass index (BMI) ≥ 30 kg m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.